Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney, Polycystic Clear all
Completed No phase listed Observational

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

NCT04407481
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Jun 11, 2026, 5:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

NCT03493802
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jun 11, 2026, 5:23 AM EDT
Completed No phase listed Observational

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

NCT02173080
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
PLD-Q
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease

NCT02697617
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Pasireotide LAR in Severe Polycystic Liver Disease

NCT01670110
View directory record Official record
Conditions
Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
Interventions
Pasireotide LAR, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Insulin and Polycystic Ovary Syndrome

NCT00683774
View directory record Official record
Conditions
PCOS
Interventions
diazoxide
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jun 11, 2026, 5:23 AM EDT
Completed No phase listed Observational

ADPKD Cohort Study

NCT02084849
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 60 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 11, 2026, 5:23 AM EDT
Completed No phase listed Observational

Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease

NCT02142101
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Jun 11, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

NCT06325644
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Ketogenic Diet, Ketone/Glucose Monitoring, CGM/CKM, Blood Draw, Body Composition, Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
Other · Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 11, 2026, 5:23 AM EDT
Withdrawn No phase listed Observational

Repository Study of Autosomal Dominant Polycystic Kidney Disease

NCT01988038
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 11, 2026, 5:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Early PKD Observational Cohort Study

NCT02936791
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
4 Years to 35 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 11, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

Daily Caloric Restriction in ADPKD

NCT04907799
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, Overweight and Obesity
Interventions
Daily caloric restriction, Standard advice control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jun 11, 2026, 5:23 AM EDT
Completed No phase listed Observational

Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease

NCT02739750
View directory record Official record
Conditions
Polycystic Kidney Diseases
Interventions
No intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jun 11, 2026, 5:23 AM EDT
Recruiting No phase listed Observational

NOX4 and Related Biomarkers in ADPKD

NCT04630613
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 11, 2026, 5:23 AM EDT
Completed No phase listed Observational

Clinical and Molecular Investigations Into Ciliopathies

NCT00068224
View directory record Official record
Conditions
Ciliopathy
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
5 Months to 80 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT03487913
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Jun 11, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT04536688
View directory record Official record
Conditions
Polycystic Kidney Disease, Autosomal Dominant
Interventions
RGLS4326
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
La Mesa, California • Los Angeles, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jun 11, 2026, 5:23 AM EDT
Not yet recruiting Phase 2 Interventional

Bempedoic Acid Therapy for Polycystic Kidney Disease

NCT07282821
View directory record Official record
Conditions
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
Drug
Lead sponsor
Kenneth Hallows
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 11, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Results available

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

NCT03749447
View directory record Official record
Conditions
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 11, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

NCT04064346
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jun 11, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD

NCT06496542
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney
Interventions
Daily caloric restriction, Standard advice control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 11, 2026, 5:23 AM EDT